Home / Intelligence / Scientific Publications / Burden of cremophor-related paclitaxel therapy on patients with ovarian cancer: A patient focused study from the United Kingdom, Germany, and Spain.
Cremophor EL (CrEL) is a solubilizer used in paclitaxel and is associated with side effects (i.e., hypersensitivity reactions, peripheral neuropathy). Current CrEL-containing therapies require long infusion times (2-4 hours) and pre-medication with steroids to manage these side-effects. However, the holistic burden of CrEL on patients is not well studied. This study aimed to characterize the burden associated with CrEL-paclitaxel treatment on patients with ovarian cancer, including clinical, safety, and quality of life (QoL) implications.
Diana Brixner, Anke-Peggy Holtorf, Ayesha Bhatia, Bhagyashree Oak, Sumudu Dehipawala, Clive Whitcher, Kate McKinley, Kyle Martin, Nandini Hadker
Key Takeaways from the ISPOR Europe 2022 Conference
Last month, Trinity attended the ISPOR Europe 2022 conference in Vienna. The main theme of the conference was “Collaborating Across Borders: Building & Using Evidence to Enable Access”, which facilitated many interesting discussions amongst different stakeholders in life sciences, including manufacturers, regulatory leaders and health economists. Among the myriad of topics covered, digital health emerged […]
The Enhancing Oncology Care Model: Where Public Health Meets Oncology Care
Executive Summary Introduction The OCM has recently concluded after five years of existence. Institutional participants advocated for a follow-up model – and following numerous reviews and analyses of the successes and points of improvement of the OCM, Centers for Medicare and Medicaid Innovation (CMMI) opted to introduce the EOM as its successor. This updated model […]
The German Financial Stabilization of Statutory Health Insurance System Act
Executive Summary: Key Policy Updates AMNOG Rebate Negotiations AMNOG* rebate negotiations will be modified to give the GKV-SV increased powers in the pricing negotiations. HIGH P&MA IMPACT: The new negotiation framework increases the threshold of added benefit required for therapies to receive a premium vs. comparator therapies, specifically by limiting the pricing of ‘No Added […]